Radium ra 223 dichloride
XOFIGO (radium Ra 223 dichloride) is an intravenous injection manufactured by Bayer HealthCare Pharmaceuticals Inc. It's a radioactive alpha-particle emitting agent used to treat prostate cancer that has spread to the bones. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | XOFIGO (radium Ra 223 dichloride) is an intravenous injection manufactured by Bayer HealthCare Pharmaceuticals Inc. It's a radioactive alpha-particle emitting agent used to treat prostate cancer that has spread to the bones. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Radium ra 223 dichloride",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Radium ra 223 dichloride — ANDA 203971 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203971"
}
]
|
| identifier | ANDA203971 |
| issued | 2016-09-16 |
| keyword |
[
"drug-manufacturers",
"health-care",
"medications",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Radium ra 223 dichloride |
